Drug intelligence / Profile preview

CuHL

Development stage: Preclinical
Modality: Small Molecules

Overview

CuHL is a copper(II)-acylhydrazone complex, chemically identified as [Cu(HL)(H2 O)](NO3 )⋅H2 O, that is being investigated for its anticancer properties, particularly against breast cancer. It has demonstrated stronger anticancer activity than cisplatin in MCF7 breast cancer cell models. Its mechanism of action involves interacting with the minor groove of DNA, leading to genotoxic effects, and inhibiting the activity of 20S proteasome subunits. These actions collectively induce apoptosis in breast cancer cells at low micromolar concentrations and reduce the formation and alter the morphology of mammospheres.

Targets

PSMB5 (Proteasome subunit beta Type-5)DNA minor groove

Beyond the preview

Go deeper on CuHL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CuHL.

Explore the full profile